Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Income from Continuing Operations (2016 - 2025)

KalVista Pharmaceuticals' Income from Continuing Operations history spans 11 years, with the latest figure at 39410000.0 for Q2 2025.

  • On a quarterly basis, Income from Continuing Operations rose 34.35% to 39410000.0 in Q2 2025 year-over-year; TTM through Apr 2025 was 16153000.0, a 71.58% increase, with the full-year FY2025 number at 91808000.0, down 74.34% from a year prior.
  • Income from Continuing Operations hit 39410000.0 in Q2 2025 for KalVista Pharmaceuticals, up from 44454000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for KALV hit a ceiling of 39410000.0 in Q2 2025 and a floor of 44454000.0 in Q4 2024.
  • Historically, Income from Continuing Operations has averaged 14355125.0 across 4 years, with a median of 28570000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 53.45% in 2024 and later skyrocketed 34.35% in 2025.
  • Tracing KALV's Income from Continuing Operations over 4 years: stood at 12520000.0 in 2021, then tumbled by 131.39% to 28970000.0 in 2023, then plummeted by 53.45% to 44454000.0 in 2024, then skyrocketed by 188.65% to 39410000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for KALV at 39410000.0 in Q2 2025, 44454000.0 in Q4 2024, and 40443000.0 in Q3 2024.